• Publications
  • Influence
Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study
Although prognostic gene expression signatures for survival in early-stage lung cancer have been proposed, for clinical application, it is critical to establish their performance across differentExpand
  • 927
  • 69
Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07.
PURPOSE This phase III clinical trial evaluated the impact on disease-free survival (DFS) of adding oxaliplatin to bolus weekly fluorouracil (FU) combined with leucovorin as surgical adjuvant therapyExpand
  • 841
  • 35
Clinical trial designs for predictive marker validation in cancer treatment trials.
Current staging and risk-stratification methods in oncology, while helpful, fail to adequately predict malignancy aggressiveness and/or response to specific treatment. Increased knowledge of cancerExpand
  • 472
  • 15
Prognostic factors in colorectal cancer
Abstract Background.—Under the auspices of the College of American Pathologists, the current state of knowledge regarding pathologic prognostic factors (factors linked to outcome) and predictive fa...
  • 257
  • 15
Vascular Injury Induces Expression of Periostin: Implications for Vascular Cell Differentiation and Migration
Objective— Periostin mRNA is among the most strongly upregulated transcripts in rat carotid arteries after balloon injury. The goal of the present study was to gain insight into the significance ofExpand
  • 141
  • 10
Endoglin Structure and Function
Determination of the functional relationship between the transforming growth factor-β (TGFβ) receptor proteins endoglin and ALK1 is essential to the understanding of the human vascular disease,Expand
  • 102
  • 8
Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer
Purpose: Veliparib, a PARP inhibitor, demonstrated clinical activity in combination with oral cyclophosphamide in patients with BRCA-mutant solid tumors in a phase I trial. To define the relativeExpand
  • 88
  • 7
  • PDF
Interlaboratory comparability study of cancer gene expression analysis using oligonucleotide microarrays.
A key step in bringing gene expression data into clinical practice is the conduct of large studies to confirm preliminary models. The performance of such confirmatory studies and the transition toExpand
  • 167
  • 6
  • PDF
Novel biochemical pathways of endoglin in vascular cell physiology
The broad role of the transforming growth factor beta (TGFβ) signaling pathway in vascular development, homeostasis, and repair is well appreciated. Endoglin is emerging as a novel, complex, andExpand
  • 121
  • 6
Phase I Trial of MS-275, a Histone Deacetylase Inhibitor, Administered Weekly in Refractory Solid Tumors and Lymphoid Malignancies
Purpose: MS-275 is a histone deacetylase inhibitor that has shown potent and unique anticancer activity in preclinical models. The aims of this phase I trial were to determine the dose-limitingExpand
  • 116
  • 5
  • PDF